Peptide Clinic Reviews: How Pepquill Scores Clinics (Our Methodology)
Peptide Clinic Reviews: How Pepquill Scores Clinics (Our Methodology)
The peptide therapy landscape has expanded dramatically over the past decade, with clinics offering everything from well-characterized, FDA-approved compounds to experimental research peptides with minimal human safety data. This expansion has created a critical problem for patients and referring providers: how do you distinguish a rigorous, science-based clinic from one prioritizing profit over evidence? Pepquill's clinic scoring methodology was developed to address this gap by providing transparent, reproducible criteria for evaluating peptide clinics across five essential dimensions.
Our approach draws from established healthcare quality frameworks, including accreditation standards from organizations like The Joint Commission and the American Association for Accreditation of Ambulatory Surgery Facilities, while incorporating specific requirements unique to peptide therapy. We recognize that peptide medicine occupies a complex regulatory space—some peptides are FDA-approved pharmaceuticals, others are 503A/503B compounded medications with limited clinical evidence, and some exist in a gray zone of research compounds available through specialized clinics. Our methodology helps navigate these distinctions without making unsupported claims about experimental compounds.
Category 1: Medical Legitimacy and Provider Credentials
The foundation of any clinical practice is the qualifications of the medical professionals operating it. Pepquill begins by verifying that clinics are overseen by licensed physicians, nurse practitioners, or physician assistants with appropriate state licensure and board certification relevant to their practice focus. We check for any disciplinary actions through state medical boards and the National Practitioner Data Bank, which is public information indicating previous malpractice settlements, license suspensions, or other regulatory actions.
Beyond credentials, we examine whether the clinic maintains a clear organizational structure with defined medical oversight. This means verifying that peptide recommendations come from qualified healthcare providers who are accountable for clinical decision-making, rather than from non-clinical staff or sales personnel. We also assess whether providers have genuine expertise in peptide pharmacology and the conditions they claim to treat. This might include continuing education in peptide science, published research contributions, or professional society involvement.
We note the distinction between providers who practice evidence-based peptide therapy and those who promote peptides as universal treatments for virtually any condition. Legitimate clinics acknowledge the current evidence limitations for specific peptides—for instance, BPC-157 has strong animal data but lacks completed human trials, whereas semaglutide is FDA-approved for weight management with extensive clinical evidence. Clinics that misrepresent research status or promise unrealistic outcomes raise significant concerns about medical integrity.
Category 2: Pharmacy Quality and Compounding Standards
For clinics dispensing compounded peptides, pharmacy quality is paramount. Pepquill verifies that compounding occurs in a facility registered with the state board of pharmacy and, ideally, accredited under USP <797> standards, which govern sterile compounding practices for injectable medications. We confirm whether the pharmacy maintains proper documentation of ingredient sourcing, including certificates of analysis for raw peptide materials and excipients.
The distinction between 503A compounding (patient-specific, from licensed prescriptions) and 503B compounding (non-patient-specific, sold to clinics and healthcare facilities) matters for transparency and regulatory oversight. 503B compounders face additional requirements under the FDA's Compliance Policy Guide and must provide stability data and sterility testing documentation. Pepquill evaluates whether clinics and their associated pharmacies clearly disclose which regulatory pathway they follow and whether their compounding claims are actually supported by testing.
We also assess quality control processes, including whether pharmacies perform sterility and potency testing on compounded batches, maintain temperature monitoring during storage and shipping, and have traceable pharmaceutical-grade supplies. Red flags include compounders claiming perfect efficacy across all patients, refusing to provide source documentation, or making unrealistic price claims that suggest they're cutting corners on ingredient quality or testing.
Category 3: Regulatory Compliance and Transparent Disclosure
Regulatory compliance extends beyond pharmacy licensing to how clinics position their peptides to patients. FDA-approved peptides like semaglutide (Ozempic, Wegovy), tirzepatide (Zepbound, Mounjaro), and various hormone replacement therapies have clear regulatory status and must be labeled and dispensed according to approved indications. Pepquill evaluates whether clinics prescribe FDA-approved peptides appropriately within their indicated uses or whether they're promoting off-label applications without clear informed consent about the experimental nature of that use.
For compounded peptides and research peptides, Pepquill assesses whether clinics provide honest disclosure about regulatory status. A legitimate clinic will explicitly state that a given peptide is "not FDA-approved for this indication" or "currently in research phases" rather than implying regulatory approval exists when it doesn't. This includes clear communication about the difference between animal studies, early human trials, and robust clinical evidence.
We examine whether informed consent processes are comprehensive, including discussion of known side effects, theoretical mechanisms from animal data, realistic expectations about efficacy, and monitoring requirements. Clinics must also comply with state laws regarding telemedicine prescribing, DEA regulations for any controlled-status peptides, and advertising standards that prohibit unsubstantiated health claims.
Category 4: Evidence-Based Practice and Honest Risk Communication
At the heart of scientific integrity is evidence-based practice. Pepquill evaluates whether clinics base their peptide protocols on published research and acknowledge the current evidence quality. This means clinics should cite specific studies when making claims, distinguish between human trials and animal research, and clearly communicate which peptides have robust clinical evidence versus those relying primarily on mechanistic plausibility or early-stage data.
We look for clinics that highlight contraindications, potential adverse effects grounded in available research, and conditions under which a peptide shouldn't be used. Honest clinics acknowledge uncertain safety profiles for experimental peptides and don't dismiss legitimate concerns about long-term effects simply because long-term data don't exist yet. They should also discuss interactions with other medications and advise patients on the importance of medical supervision rather than framing peptide therapy as a simple self-directed intervention.
Category 5: Patient Monitoring Standards and Follow-up Protocols
Finally, legitimate peptide clinics implement structured monitoring protocols. Depending on the peptide, this might include baseline lab work, periodic blood pressure monitoring, metabolic panels, or other objective measures relevant to the compound's mechanism. We assess whether clinics have clear protocols for follow-up visits, how they document patient responses, and whether they adjust protocols based on individual outcomes rather than using identical regimens across all patients.
Clinics should maintain accessible medical records and communicate clearly with patients about what to expect regarding efficacy timelines and when to seek emergency care. This category reflects a fundamental principle: peptide therapy should be supervised medicine, not an unsupervised experiment.
Through this five-category methodology, Pepquill provides evidence-based guidance to help patients and providers identify clinics that prioritize scientific rigor alongside clinical outcomes.